Lourdes R A Vaz-de-Lima1, Helena Keico Sato2, Eder Gatti Fernandes2, Ana Paula Sayuri Sato3, Lucia C Pawloski4, Maria Lucia Tondella4, Cyro A de Brito5, Expedito J A Luna6, Telma Regina M P Carvalhanas7, Euclides A de Castilho8. 1. Centro de Imunologia, Instituto Adolfo Lutz, Brazil. Electronic address: lourlima@uol.com.br. 2. Divisão de Imunização, Centro de Vigilância Epidemiológica Prof. Alexandre Vranjac, Coordenadoria de Controle de Doenças da Secretaria de Estado da Saúde de São Paulo, Brazil. 3. Departamento de Epidemiologia, Faculdade de Saúde Pública, Universidade de São Paulo, Brazil. 4. Pertussis and Diphtheria Laboratory, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, United States. 5. Centro de Imunologia, Instituto Adolfo Lutz, Brazil. 6. Instituto de Medicina Tropical da Universidade de São Paulo, Brazil. 7. Divisão de Doenças de Transmissão Respiratória, Centro de Vigilância Epidemiológica Prof. Alexandre Vranjac, Coordenadoria de Controle de Doenças da Secretaria de Estado da Saúde SP, Brazil. 8. Departamento de Medicina Preventiva, Faculdade de Medicina da Universidade de São Paulo, Brazil.
Abstract
BACKGROUND: Pertussis remains an important global public health concern, despite the presence of extensive immunization programs. Incidence and severity of pertussis are typically higher in neonates and young infants. As a strategy to protect these young infants, maternal vaccination with Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) has been recommended in Brazil. The objective of this study was to evaluate the effects of Tdap vaccination during pregnancy on the anti-pertussis toxin (PT) IgG response in mothers and their infants at birth. MATERIAL AND METHODS: Maternal and cord blood samples were collected from vaccinated (n = 243) and unvaccinated (n = 75) pregnant women, at the time of delivery, from July 2015 to August 2016 in São Paulo, Brazil. Anti-PT IgG antibodies were quantified by Enzyme-Linked Immunosorbent Assay (ELISA) and geometric mean concentrations (GMC) were calculated. Relationship between timing of vaccination and antibody concentrations were evaluated. RESULTS: Maternal and cord blood GMCs among the vaccinated group were 5.4 and 5.6 fold higher [66.5 International Units (IU)/mL and 89.8 IU/mL] compared to the unvaccinated group (12.4 IU/mL and 16.1 IU/mL), respectively (p < 0.001). Higher anti-PT IgG GMCs were observed when vaccination occurred ≥60 days before delivery compared to <60 days, suggesting that vaccination early in the third trimester may be more effective than later in pregnancy. CONCLUSION: Tdap maternal vaccination results in significantly higher anti-PT IgG in newborn infants and supports the current recommendation of the Brazilian Immunization Program.
BACKGROUND: Pertussis remains an important global public health concern, despite the presence of extensive immunization programs. Incidence and severity of pertussis are typically higher in neonates and young infants. As a strategy to protect these young infants, maternal vaccination with Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) has been recommended in Brazil. The objective of this study was to evaluate the effects of Tdap vaccination during pregnancy on the anti-pertussis toxin (PT) IgG response in mothers and their infants at birth. MATERIAL AND METHODS: Maternal and cord blood samples were collected from vaccinated (n = 243) and unvaccinated (n = 75) pregnant women, at the time of delivery, from July 2015 to August 2016 in São Paulo, Brazil. Anti-PT IgG antibodies were quantified by Enzyme-Linked Immunosorbent Assay (ELISA) and geometric mean concentrations (GMC) were calculated. Relationship between timing of vaccination and antibody concentrations were evaluated. RESULTS: Maternal and cord blood GMCs among the vaccinated group were 5.4 and 5.6 fold higher [66.5 International Units (IU)/mL and 89.8 IU/mL] compared to the unvaccinated group (12.4 IU/mL and 16.1 IU/mL), respectively (p < 0.001). Higher anti-PT IgG GMCs were observed when vaccination occurred ≥60 days before delivery compared to <60 days, suggesting that vaccination early in the third trimester may be more effective than later in pregnancy. CONCLUSION:Tdap maternal vaccination results in significantly higher anti-PT IgG in newborn infants and supports the current recommendation of the Brazilian Immunization Program.
Authors: Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn Journal: Clin Diagn Lab Immunol Date: 2004-11
Authors: Sandra L Menzies; Vijay Kadwad; Lucia C Pawloski; Tsai-Lien Lin; Andrew L Baughman; Monte Martin; Maria Lucia C Tondella; Bruce D Meade Journal: Clin Vaccine Immunol Date: 2009-10-28
Authors: Bahaa Abu Raya; Isaac Srugo; Aharon Kessel; Michael Peterman; David Bader; Ron Gonen; Ellen Bamberger Journal: Vaccine Date: 2014-08-28 Impact factor: 3.641
Authors: C Mary Healy; Marcia A Rench; Laurie S Swaim; E O'Brian Smith; Haleh Sangi-Haghpeykar; Marsenia H Mathis; Monte D Martin; Carol J Baker Journal: JAMA Date: 2018-10-09 Impact factor: 56.272
Authors: Tami H Skoff; Amy E Blain; James Watt; Karen Scherzinger; Melissa McMahon; Shelley M Zansky; Kathy Kudish; Paul R Cieslak; Melissa Lewis; Nong Shang; Stacey W Martin Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079
Authors: Lourdes R A Vaz-de-Lima; Ana Paula S Sato; Lucia C Pawloski; Eder G Fernandes; Gowrisankar Rajam; Helena K Sato; Divya Patel; Han Li; Euclides A de Castilho; Maria Lucia Tondella; Jarad Schiffer Journal: Vaccine X Date: 2021-02-16